You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery

    SBC: BIOKIER, INC.            Topic: 200

    SUMMARY Glucose homeostasis and food intake are both regulated by gut hormones secreted from enteroendocrine L- cells in the lower gut following stimulation by nutrients. This process is impaired in diabetes but is restored with delivery of dietary nutrients such as amino acids and fatty acids to the lower gut, such as after gastric bypass surgery and during fermentation of carbohydrates in the co ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    Abstract Polychromatic flow cytometry (FC) is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells. Dyes used for FC typically exhibit broad fluorescent emission bands with full-width-at-half-maximum (fwhm) values of 50–80 nm. This limits the maximum number of dyes, and thus the nu ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Low Signature Optical Guidance of Low Collateral Munitions

    SBC: CORVID TECHNOLOGIES, LLC            Topic: SOCOM061008

    At present, there are no solutions for equipping Class 1 and 2 unmanned aerial system (UAS) platforms with weapons systems that provide the capability for opportunistic engagement of high value targets (HVT). Munitions deployed on larger UAS, and other fixed-wing SOCOM assets, greatly exceed the payload capacity of Class 1 and 2 UAS assets currently in use for intelligence, surveillance, and recon ...

    SBIR Phase II 2019 Department of DefenseSpecial Operations Command
  5. Novel assay to monitor Tacrolimus levels at the point of care

    SBC: AFFINERGY, LLC            Topic: NIAID

    SUMMARY/ABSTRACT In 2016, over 33,000 organ transplants were performed in the United States, an increase of 20% over the past 5 years. Organ transplantation requires lifelong immunosuppression to prevent rejection of the transplant. Tacrolimus, a macrolide antibiotic, is one of the most effective immunosuppressants, with andgt;90% of solid organ transplant recipients receiving it as part of their ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a novel clinical assay for measuring everolimus levels

    SBC: AFFINERGY, LLC            Topic: NIAID

    SUMMARY/ABSTRACT In 2017 nearly 35,000 solid organ transplants were performed in the United States, an increase of 27% over the past ten years. Organ transplantation requires lifelong immunosuppression to prevent rejection of the transplant. Many new classes of drugs have been developed to combat the side effects and interactions common to immunosuppressants, with several agents (sirolimus, everol ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Tuned stem cell extracellular vesicles are a novel chronic wound therapeutic

    SBC: Zen-Bio, Inc.            Topic: NIA

    Project Summary The elderly population is rapidly increasing worldwide and those over 60 years old are expected to comprise 20% of the total population by 2050. These demographic changes will focus healthcare needs on those conditions more prevalent in the elderly. Chronic wounds, such as venous leg ulcers, pressure ulcers and diabetic ulcers are over-represented in the elderly population and even ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes

    SBC: SYMBERIX, INC.            Topic: 102

    The long-term objective of this project is a therapeutic adjunct to prevent chemotherapy-induced diarrhea (CID) based on a completely new mechanism of action targeting enteric bacteria. This Fast-Track SBIR proposal outlines the strategy for selecting a lead development candidate to be evaluated in investigational new drug (IND)-enabling studies to support a first-in-human trial. The focus of this ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. System for faster microarray assays and end-to-end workflow automation

    SBC: Redbud Labs, Inc.            Topic: 400

    ABSTRACTMicroarrays are an important research tool (genomics and proteomics) and clinical tool (biomarker discovery and diagnosis). Current microarray processing methods are limited by slow assay kinetics, are not amenable to automation, and require high volume of expensive reagents/buffers. Miniaturization of these technologies has been explored to improve throughput. The demand for microarrays c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Whole-organ bioreactor with integrated nondestructive 3D molecular imaging

    SBC: Sonovol, Inc.            Topic: NHLBI

    Abstract Significance: Donor tissue shortage remains a critical problem in lung transplantation. Recent advances in tissue engineering have allowed for the possibility of generating bioengineered lungs from decellularized organ scaffolds. These scaffolds, created from the donor’s tissue, become functionalized after recellularization with a patient’s own cells. However, translation of whole-lun ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government